精彩内容5月22日,国家药监局官网显示,恒瑞医药子公司山东盛迪医药申报的1类创新药瑞格列汀二甲双胍片(I)/(II)获批上市。米内网数据显示,糖尿病用药(化+生)在近年中国三大终端六大市场(统计范围详见本文末)销售规模均超过600亿元,2024年同比增长7.22%。截至目前,恒瑞医药在瑞格列汀二甲双胍片相关项目累计研发投入约7660万元。瑞格列汀二甲双胍片(I)/(II)是配合饮食控制和运动,适用...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.